VitaNova Life Sciences Corporation: diluted weighted-average shares
Diluted weighted-average shares for VitaNova Life Sciences Corporation. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All VitaNova Life Sciences Corporation financial histories
What this measure means
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
Exact concept: us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2016-01-26 to 2025-04-30. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2024-05-01 | 2025-04-30 | 25,012,270 | shares | 2025-07-24 | 10-K · 0001683168-25-005368 |
| 2023-05-01 | 2024-04-30 | 10,643,395 | shares | 2025-07-24 | 10-K · 0001683168-25-005368 |
| 2022-05-01 | 2023-04-30 | 5,871,250 | shares | 2024-07-29 | 10-K · 0001683168-24-005110 |
| 2021-05-01 | 2022-04-30 | 5,871,250 | shares | 2023-05-15 | 10-K · 0001683168-23-003352 |
| 2020-05-01 | 2021-04-30 | 5,871,250 | shares | 2022-05-16 | 10-K · 0001683168-22-003645 |
| 2017-05-01 | 2018-04-30 | 4,836,315 | shares | 2018-07-17 | 10-K · 0001699709-18-000014 |
| 2016-01-26 | 2017-01-25 | 3,500,000 | shares | 2018-07-17 | 10-K · 0001699709-18-000014 |
Related financial histories
- VitaNova Life Sciences Corporation: total assets
- VitaNova Life Sciences Corporation: total liabilities
- VitaNova Life Sciences Corporation: stockholders equity
- VitaNova Life Sciences Corporation: cash and cash equivalents
- VitaNova Life Sciences Corporation: net income or loss
- VitaNova Life Sciences Corporation: operating cash flow
- VitaNova Life Sciences Corporation: revenue
- VitaNova Life Sciences Corporation: contract revenue excluding tax
- VitaNova Life Sciences Corporation: financing cash flow
- VitaNova Life Sciences Corporation: investing cash flow
- VitaNova Life Sciences Corporation: retained earnings or deficit
- VitaNova Life Sciences Corporation: basic weighted-average shares
- VitaNova Life Sciences Corporation: basic earnings per share
- VitaNova Life Sciences Corporation: diluted earnings per share
- VitaNova Life Sciences Corporation: income tax expense or benefit
- VitaNova Life Sciences Corporation: share-based compensation expense
- VitaNova Life Sciences Corporation: operating income or loss
- VitaNova Life Sciences Corporation: current assets
- VitaNova Life Sciences Corporation: interest expense
- VitaNova Life Sciences Corporation: current liabilities
- VitaNova Life Sciences Corporation: net current accounts receivable
- VitaNova Life Sciences Corporation: operating expenses
- VitaNova Life Sciences Corporation: net inventory
- VitaNova Life Sciences Corporation: gross profit
- VitaNova Life Sciences Corporation: cost of revenue
Inspect the source
- Entity
- VitaNova Life Sciences Corporation / CIK 0001699709
- Captured
- 2026-09-21T17:23:55.214Z
- SEC response SHA-256
cbbc169c744671a8d8af3ef9e33d6f01a860c1244f31147d1b245c430a85543c
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001699709.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))